These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 3932908)

  • 1. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
    Mäenpää J; Kangas L; Grönroos M
    Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
    Mäenpää J
    Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subrenal capsule assay in choosing cytostatics for gynaecological tumours.
    Mäenpää J; Grönroos M; Kangas L
    Ann Chir Gynaecol Suppl; 1985; 199():28-30. PubMed ID: 3864390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrastructural effects of alpha and gamma interferons and cytostatics on ovarian cancer cells in the subrenal capsule assay (SRCA).
    Söderström KO; Mäenpää J; Cantell K; Kangas L; Grönroos M
    Ann Chir Gynaecol Suppl; 1985; 199():38-43. PubMed ID: 3933399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical application of subrenal capsule assay in ovarian cancer].
    Maeda K; Ushijima H; Shimamoto T; Shigematsu T; Kurano A; Watanabe Y; Jimi S; Okadome M; Mashiba H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1896-902. PubMed ID: 2592813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour effect of interferons, cytostatic drugs and their combinations in subrenal capsule assay (SRCA).
    Kangas L; Cantell K; Grönroos M; Mäenpää J; Perilä M
    Ann Chir Gynaecol Suppl; 1985; 199():60-3. PubMed ID: 2415035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
    Mäenpää JU; Heinonen E; Hinkka SM; Karnani P; Klemi PJ; Korpijaakko TA; Kuoppala TA; Laine AM; Lähde MA; Nuoranne EK
    Gynecol Oncol; 1995 Jun; 57(3):294-8. PubMed ID: 7774832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas.
    Hayward IP; Hurst T; Parsons PG; Khoo SK
    Int J Cell Cloning; 1992 May; 10(3):182-9. PubMed ID: 1613269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
    Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].
    Salzer H; Gitsch E; Dittrich C; Sevelda P; Karrer K; Schemper M; Stempel-Smekal G; Langer M; Wagner G; Rainer H
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):761-8. PubMed ID: 3908214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 15. [Chemotherapy of epithelial ovarian carcinoma].
    Bruntsch U; Gallmeier WM
    MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
    [No Abstract]   [Full Text] [Related]  

  • 16. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
    Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
    Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination chemotherapy of ovarian cancer with cisplatinum, aclarubicin and tegafur].
    Wada Y; Suzuki M; Shinagawa S; Saito Y; Nishiya I; Maki M; Yajima A; Hiroi M; Sato A
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2589-94. PubMed ID: 2505683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
    Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.